Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma

Clarke P. Anderson, Katherine K. Matthay, John P. Perentesis, Joseph P. Neglia, Howard H. Bailey, Judith G. Villablanca, Susan Groshen, Beth Hasenauer, John M. Maris, Robert C. Seeger, C. Patrick Reynolds

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity. Procedure: This pilot study (NCI #T95-0092) administered L-S,R-buthionine sulfoximine (BSO) as a bolus followed by 72hr continuous infusion of either 0.75g/m2/hr (level 1) or 1.0g/m2/hr (level 2) and melphalan (L-PAM) (15mg/m2 bolus at hour 48 of BSO infusion). GSH in blood mononuclear cells and bone marrow was measured by enzymatic assay, BSO in plasma by HPLC. Results: Thirty two patients received 58 courses of therapy (median 1, range 1-4 courses). Blood mononuclear cell GSH decreased (48hr) to 47%±15.7%. Level 2 mean steady-state concentration (Css) for BSO=524±207μM and peak L-PAM concentration=3.32±1.2μM. Grade 3-4 leukopenia and thrombocytopenia were common. There were two deaths from CNS toxicity and acute tubular necrosis; one had a large, intracranial mass, both were receiving cephalosporin antibiotics. No other significant toxicities were seen. There were six responses (five partial and, one mixed) representing an 18% response rate; four/six responses occurred in patients that relapsed following myeloablative therapy and included a 98% reduction in volume (cm3) of a pelvic mass, and three/five patients with >3log reduction of tumor in marrow as measured by immunocytology (sensitivity 1/105). Conclusions: BSO/L-PAM has activity against recurrent high-risk NB. Exclusion of cephalosporin antibiotics in future clinical trials of BSO may diminish the potential for serious renal and CNS toxicity.

Original languageEnglish (US)
Pages (from-to)1739-1746
Number of pages8
JournalPediatric Blood and Cancer
Volume62
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Buthionine Sulfoximine
Melphalan
Neuroblastoma
Cephalosporins
Blood Cells
Bone Marrow
Alkylating Agents
Leukopenia
Enzyme Assays
Glutathione
Necrosis
High Pressure Liquid Chromatography
Clinical Trials
Kidney
Therapeutics

Keywords

  • Glutathione
  • Melphalan
  • Neuroblastoma
  • Reactive oxygen species

Cite this

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. / Anderson, Clarke P.; Matthay, Katherine K.; Perentesis, John P.; Neglia, Joseph P.; Bailey, Howard H.; Villablanca, Judith G.; Groshen, Susan; Hasenauer, Beth; Maris, John M.; Seeger, Robert C.; Reynolds, C. Patrick.

In: Pediatric Blood and Cancer, Vol. 62, No. 10, 01.10.2015, p. 1739-1746.

Research output: Contribution to journalArticle

Anderson, CP, Matthay, KK, Perentesis, JP, Neglia, JP, Bailey, HH, Villablanca, JG, Groshen, S, Hasenauer, B, Maris, JM, Seeger, RC & Reynolds, CP 2015, 'Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma', Pediatric Blood and Cancer, vol. 62, no. 10, pp. 1739-1746. https://doi.org/10.1002/pbc.25594
Anderson, Clarke P. ; Matthay, Katherine K. ; Perentesis, John P. ; Neglia, Joseph P. ; Bailey, Howard H. ; Villablanca, Judith G. ; Groshen, Susan ; Hasenauer, Beth ; Maris, John M. ; Seeger, Robert C. ; Reynolds, C. Patrick. / Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 10. pp. 1739-1746.
@article{9956a01968a34df6be9481a619939302,
title = "Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma",
abstract = "Purpose: To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity. Procedure: This pilot study (NCI #T95-0092) administered L-S,R-buthionine sulfoximine (BSO) as a bolus followed by 72hr continuous infusion of either 0.75g/m2/hr (level 1) or 1.0g/m2/hr (level 2) and melphalan (L-PAM) (15mg/m2 bolus at hour 48 of BSO infusion). GSH in blood mononuclear cells and bone marrow was measured by enzymatic assay, BSO in plasma by HPLC. Results: Thirty two patients received 58 courses of therapy (median 1, range 1-4 courses). Blood mononuclear cell GSH decreased (48hr) to 47{\%}±15.7{\%}. Level 2 mean steady-state concentration (Css) for BSO=524±207μM and peak L-PAM concentration=3.32±1.2μM. Grade 3-4 leukopenia and thrombocytopenia were common. There were two deaths from CNS toxicity and acute tubular necrosis; one had a large, intracranial mass, both were receiving cephalosporin antibiotics. No other significant toxicities were seen. There were six responses (five partial and, one mixed) representing an 18{\%} response rate; four/six responses occurred in patients that relapsed following myeloablative therapy and included a 98{\%} reduction in volume (cm3) of a pelvic mass, and three/five patients with >3log reduction of tumor in marrow as measured by immunocytology (sensitivity 1/105). Conclusions: BSO/L-PAM has activity against recurrent high-risk NB. Exclusion of cephalosporin antibiotics in future clinical trials of BSO may diminish the potential for serious renal and CNS toxicity.",
keywords = "Glutathione, Melphalan, Neuroblastoma, Reactive oxygen species",
author = "Anderson, {Clarke P.} and Matthay, {Katherine K.} and Perentesis, {John P.} and Neglia, {Joseph P.} and Bailey, {Howard H.} and Villablanca, {Judith G.} and Susan Groshen and Beth Hasenauer and Maris, {John M.} and Seeger, {Robert C.} and Reynolds, {C. Patrick}",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/pbc.25594",
language = "English (US)",
volume = "62",
pages = "1739--1746",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma

AU - Anderson, Clarke P.

AU - Matthay, Katherine K.

AU - Perentesis, John P.

AU - Neglia, Joseph P.

AU - Bailey, Howard H.

AU - Villablanca, Judith G.

AU - Groshen, Susan

AU - Hasenauer, Beth

AU - Maris, John M.

AU - Seeger, Robert C.

AU - Reynolds, C. Patrick

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Purpose: To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity. Procedure: This pilot study (NCI #T95-0092) administered L-S,R-buthionine sulfoximine (BSO) as a bolus followed by 72hr continuous infusion of either 0.75g/m2/hr (level 1) or 1.0g/m2/hr (level 2) and melphalan (L-PAM) (15mg/m2 bolus at hour 48 of BSO infusion). GSH in blood mononuclear cells and bone marrow was measured by enzymatic assay, BSO in plasma by HPLC. Results: Thirty two patients received 58 courses of therapy (median 1, range 1-4 courses). Blood mononuclear cell GSH decreased (48hr) to 47%±15.7%. Level 2 mean steady-state concentration (Css) for BSO=524±207μM and peak L-PAM concentration=3.32±1.2μM. Grade 3-4 leukopenia and thrombocytopenia were common. There were two deaths from CNS toxicity and acute tubular necrosis; one had a large, intracranial mass, both were receiving cephalosporin antibiotics. No other significant toxicities were seen. There were six responses (five partial and, one mixed) representing an 18% response rate; four/six responses occurred in patients that relapsed following myeloablative therapy and included a 98% reduction in volume (cm3) of a pelvic mass, and three/five patients with >3log reduction of tumor in marrow as measured by immunocytology (sensitivity 1/105). Conclusions: BSO/L-PAM has activity against recurrent high-risk NB. Exclusion of cephalosporin antibiotics in future clinical trials of BSO may diminish the potential for serious renal and CNS toxicity.

AB - Purpose: To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity. Procedure: This pilot study (NCI #T95-0092) administered L-S,R-buthionine sulfoximine (BSO) as a bolus followed by 72hr continuous infusion of either 0.75g/m2/hr (level 1) or 1.0g/m2/hr (level 2) and melphalan (L-PAM) (15mg/m2 bolus at hour 48 of BSO infusion). GSH in blood mononuclear cells and bone marrow was measured by enzymatic assay, BSO in plasma by HPLC. Results: Thirty two patients received 58 courses of therapy (median 1, range 1-4 courses). Blood mononuclear cell GSH decreased (48hr) to 47%±15.7%. Level 2 mean steady-state concentration (Css) for BSO=524±207μM and peak L-PAM concentration=3.32±1.2μM. Grade 3-4 leukopenia and thrombocytopenia were common. There were two deaths from CNS toxicity and acute tubular necrosis; one had a large, intracranial mass, both were receiving cephalosporin antibiotics. No other significant toxicities were seen. There were six responses (five partial and, one mixed) representing an 18% response rate; four/six responses occurred in patients that relapsed following myeloablative therapy and included a 98% reduction in volume (cm3) of a pelvic mass, and three/five patients with >3log reduction of tumor in marrow as measured by immunocytology (sensitivity 1/105). Conclusions: BSO/L-PAM has activity against recurrent high-risk NB. Exclusion of cephalosporin antibiotics in future clinical trials of BSO may diminish the potential for serious renal and CNS toxicity.

KW - Glutathione

KW - Melphalan

KW - Neuroblastoma

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84939567183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939567183&partnerID=8YFLogxK

U2 - 10.1002/pbc.25594

DO - 10.1002/pbc.25594

M3 - Article

C2 - 26153194

AN - SCOPUS:84939567183

VL - 62

SP - 1739

EP - 1746

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -